<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68977">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121340</url>
  </required_header>
  <id_info>
    <org_study_id>R34EY024299</org_study_id>
    <nct_id>NCT02121340</nct_id>
  </id_info>
  <brief_title>Collaborative Care for Depression and Diabetic Retinopathy in African Americans</brief_title>
  <acronym>CC-DDR</acronym>
  <official_title>Collaborative Care for Depression and Diabetic Retinopathy in African Americans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Wills Eye</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this feasibility/pilot study, we will develop, refine, and evaluate the feasibility of a
      novel mental health/ophthalmologic intervention called, &quot;Collaborative Care for Depression
      and Diabetic Retinopathy&quot; (CC-DDR), which aims to treat depression and lower HbA1C in older
      African Americans with mild-to-moderate diabetic retinopathy (DR) and comorbid depression.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Specific Aims are:

        1. To develop the CC-DDR treatment protocol.  This will involve:

             1. Creating an initial version of the CC-DDR treatment protocol.

             2. Refining the protocol based on input from an expert panel with expertise in DR,
                depression, and culturally relevant interventions for diabetes in older African
                Americans.

             3. Developing a tool to assess interventionist treatment adherence and competence.

        2. To conduct an open trial of CC-DDR with 40 participants who have poorly controlled
           diabetes, depression, and mild or moderate DR.  During this open trial we will:

             1. Evaluate the feasibility of CC-DDR.

             2. Refine the CC-DDR treatment protocol by incorporating feedback from participants,
                community health care workers (CHWs), ophthalmologists, and the expert panel.

             3. Refine procedures for recruitment and retention, outcome assessment, monitoring
                treatment fidelity, CHW training and supervision, quality assurance, and study
                administration, based on input from investigators, CHWs, participants, and the
                expert panel.

             4. Examine CC-DDR's impact on depression severity; diabetes self-management
                practices; HbA1C level; blood pressure;  adherence  to the ophthalmologist
                treatment plan; vision function; quality of  life; and satisfaction with CC-DDR.

        3. To complete a Manual of Procedures that characterizes all aspects of the planned
           efficacy trial of CC-DDR.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglobin A1c</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in hemoglobin A1c from baseline to 12 months</description>
  </primary_outcome>
  <other_outcome>
    <measure>Depression</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement in depressive symptoms from baseline  to 12 months</description>
  </other_outcome>
  <other_outcome>
    <measure>Progression of diabetic retinopathy</measure>
    <time_frame>Baseline to 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Diabetes self management</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement from baseline to 12 months</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Diabetic Retinopathy</condition>
  <arm_group>
    <arm_group_label>Behavioral Activation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CC-DDR is a novel mental health/ophthalmologic intervention that we are designing to treat depression and lower HbA1C levels in older AAs with mild-to-moderate DR and comorbid depression. Community Health Workers, who match participants in race and cultural background, will work with ophthalmologists in the retina clinic to educate participants on the links between depression, HbA1C, and DR, and will extend care into the home where they will use Behavioral Activation to treat depression and improve diabetes self-management skills.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Usual Care</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioral Activation</intervention_name>
    <arm_group_label>Behavioral Activation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. African-American race

          2. age ≥ 65 years

          3. type 2 diabetes

          4. mild or moderate nonproliferative DR with or without macular edema

          5. depressive symptoms (i.e., Patient Health Questionnaire-9 score ≥5)

          6. HbA1C ≥ 7.0%

        Exclusion Criteria:

          1. treated proliferative DR

          2. global cognitive impairment (i.e., Mini Mental Status score ≤ 20)

          3. psychiatric diagnosis other than depression

          4. treatment for depression started in the previous 3 months

          5. life expectancy under 2 years
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Barry Rovner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robin Casten, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Robin Casten, PhD</last_name>
    <phone>215-503-1250</phone>
    <email>Robin.Casten@Jefferson.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wills Eye Hospital</name>
      <address>
        <city>Phiadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Julia Haller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Barry Rovner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 21, 2014</lastchanged_date>
  <firstreceived_date>April 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Thomas Jefferson University</investigator_affiliation>
    <investigator_full_name>Barry Rovner</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Health disparities</keyword>
  <keyword>African American</keyword>
  <keyword>Geriatric</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
